Sex Differences in Hypertrophic Cardiomyopathy.
S, A., N, T., A, S., R, K., R, L., E, R., & R, R. (2026). Sex Differences in Hypertrophic Cardiomyopathy.. Current cardiology reports. https://doi.org/10.1007/s11886-026-02387-z
S A, N T, A S, R K, R L, E R, et al. Sex Differences in Hypertrophic Cardiomyopathy.. Current cardiology reports. 2026; doi: 10.1007/s11886-026-02387-z
S A, N T, A S, et al. Sex Differences in Hypertrophic Cardiomyopathy.[J]. Current cardiology reports. 2026. DOI: 10.1007/s11886-026-02387-z.
@article{s2026,
author = {Abraham S and Tapaskar N and Saji A and Kanneganti R and Lyubarova R and Rashed E and Rao R},
title = {Sex Differences in Hypertrophic Cardiomyopathy.},
journal = {Current cardiology reports},
year = {2026},
doi = {10.1007/s11886-026-02387-z},
note = {PMID: 42423858},
}
TY - JOUR AU - Abraham S AU - Tapaskar N AU - Saji A AU - Kanneganti R AU - Lyubarova R AU - Rashed E AU - Rao R TI - Sex Differences in Hypertrophic Cardiomyopathy. T2 - Current cardiology reports PY - 2026 DO - 10.1007/s11886-026-02387-z AN - PMID:42423858 ER -
PURPOSE OF REVIEW: This review summarizes contemporary evidence regarding sex-based differences in hypertrophic cardiomyopathy (HCM), including disparities in presentation, disease progression, outcomes, and management. RECENT FINDINGS: Women with HCM are frequently diagnosed later than men and often present with more advanced symptoms, greater left ventricular outflow tract obstruction, worse diastolic dysfunction, and higher heart failure burden. Despite similar rates of ventricular arrhythmias and sudden cardiac death, women experience greater progression to advanced heart failure and poorer quality of life. Emerging evidence suggests that current sex-neutral risk assessment tools may underestimate disease severity in women. Cardiac myosin inhibitors demonstrate similar efficacy across sexes, with some studies suggesting greater symptomatic improvement in women. Persistent disparities in referral patterns, access to specialized care, and representation in clinical trials continue to affect outcomes. Sex-specific differences significantly impact the phenotype, progression, and management of HCM. Greater recognition of these differences is essential to improve individualized care and reduce disparities in outcomes for women with HCM.